findmyKOL
Clinical trialNCT05781360TerminatedPhase 1Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

SponsorJiangsu Simcere Pharmaceutical Co., Ltd.Enrollment192Locally Advanced Unresectable or Metastatic Solid Tumor
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • the First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana, United States

  • Nyu Langone

    New York, New York, United States

  • University of Texas Md Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
8 Mar 2023
Primary completion
25 May 2024
Completion
25 May 2024
Last update posted
20 Dec 2024
Registered enrollment
192
Registry id
NCT05781360

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.